Skip to main content
. 2017 Oct 19;10:5065–5076. doi: 10.2147/OTT.S142620

Figure 1.

Figure 1

Progression-free survival for patients with metastatic gastric cancer receiving chemotherapy and trastuzumab (A, P=0.02) or chemotherapy only (B, P=0.83) as the first-line treatment, according to FcγRIIA polymorphisms (H/R or R/R vs H/H).

Abbreviation: FcγR, Fc γ receptor.